Human bladder cancer is the sixth most common cancer in the United States. Discovery and evaluation of new alternative medications is of tremendous importance for reducing the bladder cancer mortality. Chinese herb Gnetum Cleistostachyun has been used for treatment of bladder cancers for centuries, but its bioactive components and anti-cancer mechanisms have been barely explored. Our recent studies discovered that Isorhapontigenin (ISO), a new derivative of stilbene compound isolated from this herb, exhibited multiple anti- cancer activities in human high grade invasive bladder cancer cells. Our preliminary studies provided strong evidence on ISO inhibition of tumor growth both in vitro and in vivo. In addition, the robust induction of SESN2 and BECN1, the important autophagy regulator and effector, have been shown as a critical event for ISO's anti-cancer activity in vitro, as depletion of either SESN2 or BECN1 significantly impaired the capacity of ISO to inhibit tumor cell growth. However, many questions, such as whether ISO affects cell invasion and tumor metastasis in vivo, and whether SESN2/BECN1 mediates ISO's in vivo activity, as well as upstream regulators being responsible for their upregulation by ISO, remain unknown. Therefore, in this application, three specific aims were proposed to address key events in SESN2/BECN1-mediated ISO tumor inhibition.
The first Aim will target the potential upstream regulators and epigenetic mechanism that mediate ISO-induced upregulation of SESN2 and BECN1.
The second Aim will employ both in vitro and in vivo approaches to address the functional relevance of SESN2 and BECN1 as well as new candidates obtained from Aim 1 in ISO inhibition of tumor invasion and metastasis. The last Aim will focus on in vivo role of SESN2 and BECN1 in BC development using BBN-induced mouse bladder carcinogenic model. The results obtained from the proposed studies will determine whether ISO specifically initiates the SESN2/BECN1/autophagy pathway to inhibit bladder tumor formation, invasion, and metastasis. The success of this proposal will facilitate our understanding of the molecular basis of ISO anti-cancer activity and will also provide new insights for developing a better therapeutic strategy for human high grade invasive bladder cancer.
Isorhapontigenin (ISO), an active gradient of Chinese herb that has been used to treat bladder cancer for centuries, displayed an extraordinary anti-cancer activity both in vitro and in vivo. This proposal aims to investigate the molecular mechanism that underlying ISO induction of autophagy and its contribution to ISO inhibition of bladder cancer formation, invasion and metastasis. The success of this research proposal will significantly improve our understanding of the molecular basis of ISO anti-cancer activity and will provide new insights for developing a better therapeutic strategy for human high-grade invasive bladder cancer.
|Li, Xin; Tian, Zhongxian; Jin, Honglei et al. (2018) Decreased c-Myc mRNA Stability via the MicroRNA 141-3p/AUF1 Axis Is Crucial for p63? Inhibition of Cyclin D1 Gene Transcription and Bladder Cancer Cell Tumorigenicity. Mol Cell Biol 38:|
|Guo, Xirui; Huang, Haishan; Jin, Honglei et al. (2018) ISO, via Upregulating MiR-137 Transcription, Inhibits GSK3?-HSP70-MMP-2 Axis, Resulting in Attenuating Urothelial Cancer Invasion. Mol Ther Nucleic Acids 12:337-349|
|Hua, Xiaohui; Xu, Jiheng; Deng, Xu et al. (2018) New compound ChlA-F induces autophagy-dependent anti-cancer effect via upregulating Sestrin-2 in human bladder cancer. Cancer Lett 436:38-51|
|Peng, Minggang; Wang, Jingjing; Zhang, Dongyun et al. (2018) PHLPP2 stabilization by p27 mediates its inhibition of bladder cancer invasion by promoting autophagic degradation of MMP2 protein. Oncogene :|